Clinical Trial Update: A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET [Phase 2]

View source ↗

Summary

A Phase 2 trial is investigating the safety and activity of combining cabozantinib with lanreotide in metastatic well-differentiated neuroendocrine neoplasms an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Well-differentiated Neuroendocrine Neoplasm

Drugs mentioned

• Lanreotide (lanreotide)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Metastatic Well Differentiated Neuroendocrine Neoplasm, Neuroendocrine Tumors | Phase 2 | Status: UNKNOWN